{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-002842","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.846067+00:00","generated_at":"2026-05-24T21:10:56.086276+00:00","sec_items":["5.07"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Coherus stockholders approve UDENYCA sale to Intas Pharmaceuticals","bullets":["Stockholders voted 70,989,067 FOR, 968,989 AGAINST, 621,431 ABSTAIN; majority threshold was 57,945,094.","Approval clears key milestone for divestiture of UDENYCA (pegfilgrastim-cbqv) franchise under Dec 2, 2024 Asset Purchase Agreement.","Special Meeting held virtually on March 11, 2025; 115,890,186 shares outstanding as of Jan 27, 2025 record date."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-002842","json":"https://secwatch.observer/filing/0001558370-25-002842.json","markdown":"https://secwatch.observer/filing/0001558370-25-002842.md","text":"https://secwatch.observer/filing/0001558370-25-002842.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025002842/0001558370-25-002842-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837025002842/chrs-20250311x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:10:56.086276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}